Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 144,900 shares, a growth of 23.1% from the June 30th total of 117,700 shares. Based on an average trading volume of 277,800 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.7% of the company’s shares are short sold.
Xilio Therapeutics Stock Down 3.0 %
Shares of NASDAQ:XLO opened at $0.98 on Tuesday. The firm has a market cap of $36.17 million, a price-to-earnings ratio of -0.38 and a beta of -0.09. Xilio Therapeutics has a 12 month low of $0.49 and a 12 month high of $2.94. The company’s fifty day simple moving average is $0.99 and its 200 day simple moving average is $0.92.
Xilio Therapeutics (NASDAQ:XLO – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.29). Research analysts expect that Xilio Therapeutics will post -1.48 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Xilio Therapeutics
About Xilio Therapeutics
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.
See Also
- Five stocks we like better than Xilio Therapeutics
- Trading Halts Explained
- Survey: Top 175 Fittest Retirement Locations in America
- Investing In Automotive Stocks
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- ETF Screener: Uses and Step-by-Step Guide
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.